N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Intra-abdominal Pressure in Peritoneal Dialysis Patients
Peritoneal Dialysis
Primary: Intra-Abdominal Pressure (IAP) — -0.5; -0.2; -1.2 mm Hg
N/A N=671 Prevention of Peritonitis in Peritoneal Dialysis
Kidney Failure, Chronic · Peritoneal Dialysis-associated Peritonitis · Dialysis Capd Infection
Primary: Time to the First Dialysis-associated Peritonitis Episode in the Retraining Group and the Control Group — 381; 368 Days to first peritonitis episode — p=0.51
N/A N=73 Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Number of Participants With Negative Fluid Balance on Postop Day 1 — 21; 29 Participants
N/A N=22 Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure
Hypoplastic Left Heart Syndrome
Primary: Time to First Post-operative Negative 24 Hour Fluid Balance — 2.7; 2.67 Days
Phase 4 N=7 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
Continuous Ambulatory Peritoneal Dialysis · End Stage Renal Disease
Primary: Volume of Distribution, Central Compartment (Vc) — 2.78 Liters (L)
N/A N=208 Improving Care for Peritoneal Dialysis Patients With the CKD-PD App
Kidney Failure, Chronic · Peritoneal Dialysis Complication
Primary: Clinical Interventions for Over Hydration — 473; 164 clinical interventions
Phase 2 N=4 L-Carnitine in Peritoneal Dialysis
End-Stage Renal Disease
Primary: Long Dwell Ultrafiltration — 2167 milliliters
Phase 2 N=20 Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Chronic Renal Failure
Primary: Change in Daily Urine Volume From Baseline — 18.3 mL
Phase 4 N=10 Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
Infectious Peritonitis
Primary: Determine Dalbavancin Plasma Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration — 40573.2; 13532.3 mg*h/L
Phase 4 N=149 Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Primary: Blood Albumin — 4.02 g/L — p=<0.0125
N/A N=7 Direct Peritoneal Resuscitation Effects in the Damage Control Patient
Traumatic Injury
Primary: Number of Participants With Morbidity — 0; 0 number of participants
N/A N=80 Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
Peritoneal Dialysis Associated Peritonitis
Primary: Complete Cure Rate — 32; 31 Participants
Phase 3 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 1 N=4 Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis
Peritoneal Dialysis-associated Peritonitis
Primary: Maximum Total Plasma Concentration (Cmax) — 28.7 mg/L
N/A N=21 Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Phase 4 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
N/A N=100 Peritoneal Damage in Laparoscopic Surgery
Peritoneal Damage
Primary: Inflammatory Peritoneal Markers — 0.80; 1.14; 4.26; 3.24 log (pg/ml) — p=0.058
N/A N=1,075 Quality of Life and Depression in Dialysis Patients
Chronic Kidney Disease Stage 5
Primary: Change of Kidney Disease Quality of Life Short Form 1.3 (KDQOL SF 1.3) Score and Beck Depression Inventory(BDI) Score From Visit 1 Period — 1.22; -1.50; 1.62; 0.46 units…
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
N/A N=140 Dietary Education Intervention Impact on Dietary Protein Intake in PD
Dietary Modification
Primary: Normalized Protein Catabolic Rate (nPCR) — 1.038; 0.930 g/(kg*d)
N/A N=101 Observational Study of Complications Related to Use of Peripherally Inserted Central Catheters
Adult Patients With Peripherally Inserted Central Catheters
Primary: Rate of PICC Line Occlusions — 37 percentage of enrolled subjects
N/A N=223 Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis
Renal Impairment · Renal Anemia of Chronic Kidney Disease
Primary: Percentage of Participants With Hemoglobin Values in the Range of 11-12 Grams Per Deciliter (g/dL) During the Evaluation Period of Visit 7 (Month 7) to Visit 9 (Month 9)…
Phase 1 N=30 Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
Peritoneal Dialysis (PD) · Anemia · Chronic Kidney Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered in Patients on Chronic Peritoneal Dialysis: Maximum Concentration (Cmax) of Serum Total Iron After Intraperitoneal…
Phase 3 N=121 Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
Anemia
Primary: Mean Change From Baseline to the Highest Hemoglobin up to Day 71 — 1.3; .7 g/dL
Phase 4 N=55 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
Hyperphosphatemia
Primary: Phosphorus Levels — 5.3; 5.6; 5.4; 6 mg/dL
N/A N=16 Expanded Hemodialysis Versus Online Hemodiafiltration
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
Phase 4 N=60 Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients
Disorders Associated With Peritoneal Dialysis
Primary: Adjusted HOMA Index Score at 3 Months Using Baseline Values as a Covariate and Groups as the Fixed Factor — 1.49; 1.89 IR score
Phase 4 N=8 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
Phase 2 N=20 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants